Skip to main content
Triangle logo TriangleGet started

L19IL2 (NCT06284590)

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients: a one-minute explainerNCT062845901 min

L19IL2 trial for Melanoma Stage III (NCT06284590). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with unresectable stage III–IV melanoma resistant to PD-1/PD-L1 treatment, with injectable lesions. Visceral spread is limited; BRAF-mutated cases have additional prior-treatment requirements.

The idea: injections of L19IL2, L19TNF, or both aim to concentrate immune signals in tumors. Patients are randomly assigned to weekly injections for four weeks, all with intravenous pembrolizumab every three weeks. Researchers measure tumor shrinkage; pembrolizumab may continue for up to two years.

This phase 2 study plans 162 patients. Philogen sponsors it; Hartford and New York have recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.